Paper41379101
Discovery of Zilucoplan: A Complement C5 Inhibitor for Treatment of Anti-Acetylcholine Receptor (AChR) Antibody-Positive Generalized Myasthenia Gravis (gMG).
Ye P and 8 others. J Med Chem, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Discovery of Zilucoplan: A Complement C5 Inhibitor for Treatment of Anti-Acetylcholine Receptor (AChR) Antibody-Positive Generalized Myasthenia Gravis (gMG). Papers, record 41379101. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41379101
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Discovery of Zilucoplan: A Complement C5 Inhibitor for Treatment of Anti-Acetylcholine Receptor (AChR) Antibody-Positive Generalized Myasthenia Gravis (gMG).
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Myasthenia Gravis | Major topic |
| Complement C5 | Major topic |
| Peptides, Cyclic | Major topic |
| Receptors, Cholinergic | Major topic |
| Humans | |
| Animals | |
| Drug Discovery | |
| Structure-Activity Relationship |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31050279 | Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31050279 | PubMed |
| 2 | 19730437 | Complement regulators and inhibitory proteins. | Nat Rev Immunol | 2009 | https://conductscience.org/library/papers/19730437 | PubMed |
| 3 | 24521109 | Genetic variants in C5 and poor response to eculizumab. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24521109 | PubMed |
| 4 | 16990386 | The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16990386 | PubMed |
| 5 | 32582144 | Complement Inhibitor Therapy for Myasthenia Gravis. | Front Immunol | 2020 | https://conductscience.org/library/papers/32582144 | PubMed |
| 6 | 35730504 | Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. | Expert Rev Clin Immunol | 2022 | https://conductscience.org/library/papers/35730504 | PubMed |
| 7 | 30395448 | RNA Display Methods for the Discovery of Bioactive Macrocycles. | Chem Rev | 2019 | https://conductscience.org/library/papers/30395448 | PubMed |
| 8 | 32882310 | C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. | Ophthalmology | 2021 | https://conductscience.org/library/papers/32882310 | PubMed |
| 9 | 26308095 | Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. | J Med Chem | 2015 | https://conductscience.org/library/papers/26308095 | PubMed |
| 10 | 29655452 | Treatment of Myasthenia Gravis. | Neurol Clin | 2018 | https://conductscience.org/library/papers/29655452 | PubMed |
| 11 | 24157402 | mRNA display: from basic principles to macrocycle drug discovery. | Drug Discov Today | 2014 | https://conductscience.org/library/papers/24157402 | PubMed |
| 12 | 22094817 | In vitro selection of unnatural cyclic peptide libraries via mRNA display. | Methods Mol Biol | 2012 | https://conductscience.org/library/papers/22094817 | PubMed |
| 13 | 8554512 | Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. | Biochem J | 1995 | https://conductscience.org/library/papers/8554512 | PubMed |
| 14 | 37622108 | Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation. | Front Immunol | 2023 | https://conductscience.org/library/papers/37622108 | PubMed |
| 15 | 33170686 | Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design. | J Med Chem | 2020 | https://conductscience.org/library/papers/33170686 | PubMed |
| 16 | 31209353 | A small-molecule inhibitor of C5 complement protein. | Nat Chem Biol | 2019 | https://conductscience.org/library/papers/31209353 | PubMed |
| 17 | 33730455 | Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33730455 | PubMed |
| 18 | 33792453 | Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis. | Expert Opin Investig Drugs | 2021 | https://conductscience.org/library/papers/33792453 | PubMed |
| 19 | 15049843 | Facile preparation of disulfide-bridged peptides using the polymer-supported oxidant CLEAR-OX. | J Pept Res | 2004 | https://conductscience.org/library/papers/15049843 | PubMed |
| 20 | 24088106 | Eculizumab in atypical hemolytic-uremic syndrome. | N Engl J Med | 2013 | https://conductscience.org/library/papers/24088106 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42866003 | Development of a Lactam-Bridged Peptide as Interleukin-11 Antagonist for Renal Fibrosis Treatment. | ACS Med Chem Lett | 2026 | https://conductscience.org/library/papers/42866003 | PubMed |
| 42714778 | Neuroimmune interactions: from molecular mechanisms to therapeutic targets. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42714778 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| C5 | 727 | PubTator's text mining | https://conductscience.org/library/genes/727 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41379101
GET https://conductscience.org/api/papers/v1/41379101/references?page=2